Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118235) titled 'Clinical Study on the Improvement of Sepsis-Associated ARDS via Activation of the TP53-PLTP/S1P Pathway by Xuebijing Injection' on Feb. 3.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Su Bei People's Hospital, Jiangsu Province
Condition:
Sepsis-Associated Acute Respiratory Distress Syndrome
Intervention:
Interventional Group :Dissolve 100 mL of Xuebijing Injection in 100 mL of 0.9% sodium chloride solution, and administer by intravenous drip over 30-40 minutes, every 12 hours, for 5 consecutive days.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 20...